Comparative Pharmacology
Head-to-head clinical analysis: ALYMSYS versus TERIFLUNOMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYMSYS versus TERIFLUNOMIDE.
ALYMSYS vs TERIFLUNOMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vascular endothelial growth factor (VEGF) inhibitor; binds to VEGF-A and prevents interaction with VEGFR-1 and VEGFR-2, reducing angiogenesis and tumor growth.
Teriflunomide inhibits dihydroorotate dehydrogenase, a key enzyme in de novo pyrimidine synthesis, thereby reducing proliferation of activated T and B lymphocytes.
Bevacizumab 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks in combination with chemotherapy.
7 mg orally once daily with or without food.
None Documented
None Documented
Approximately 18-32 days (terminal half-life), reflecting slow clearance typical of monoclonal antibodies; supports every-3-week dosing interval.
Clinical Note
moderateTeriflunomide + Gatifloxacin
"Teriflunomide may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateTeriflunomide + Rosoxacin
"Teriflunomide may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateTeriflunomide + Trovafloxacin
"Teriflunomide may increase the neuroexcitatory activities of Trovafloxacin."
Clinical Note
moderateTeriflunomide + Nalidixic acid
Terminal half-life approximately 18-19 days (range 10-30 days) due to enterohepatic recirculation. Clinical context: Requires prolonged elimination (up to 2 years to reach undetectable levels) due to slow clearance; accelerated elimination with cholestyramine or activated charcoal may be needed for toxicity.
Primarily hepatic metabolism; <5% excreted unchanged in urine; biliary/fecal excretion of metabolites accounts for >95% of elimination.
Primarily biliary/fecal (approximately 60% unchanged drug and metabolites in feces, 23% in urine). Renal elimination of unchanged drug is minimal (<0.5%). Enterohepatic recycling contributes to long half-life.
Category C
Category C
Immunomodulator
Immunomodulator
"Teriflunomide may increase the neuroexcitatory activities of Nalidixic acid."